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Summary 
In this controlled human malaria infection study with PfSPZ Challenge, individuals with 
serological evidence of higher recent and cumulative malaria exposure had a longer prepatent 
period, lower mean parasite density at the time of treatment and fewer symptoms of malaria. 
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ABSTRACT 
Background 
We assessed the impact of exposure to P. falciparum on parasite kinetics, clinical symptoms, and 
functional immunity after controlled human malaria infection (CHMI) in two cohorts with 
different levels of previous malarial exposure. 
 
Methods 
Nine adult males with high (sero-high) and ten with low (sero-low) previous exposure received 
3200 PfSPZ of PfSPZ Challenge by direct venous inoculation and were followed for 35 days for 
parasitemia by thick blood smear (TBS) and quantitative polymerase chain reaction (qPCR). End 
points were time to parasitemia, adverse events and immune responses.   
 
Results 
Ten of Ten (100%) volunteers in the sero-low and 7 of 9 (77.8%) in the sero-high group 
developed parasitemia detected by TBS in the first 28 days (p = 0.125). The median time to 
parasitemia was significantly shorter in the sero-low group [9 days (7.5-11.0) vs.11.3 days (7.5-
18.0), log rank test, p=0.005]. Antibody recognition of sporozoites was significantly higher in 
the sero-high (median 17.93 AU, IQR 12.95-24) than the sero-low volunteers (median 10.54 AU, 
IQR 8.36-12.12); p=0.006. Presence of blood-stage antibodies was also significantly higher 
(p=0.0003) in the sero-high group (median 50.98 AU, IQR 22.46-65.07) than in the sero-low 
group (median 3.16 AU, IQR 2.43-8.71). Growth inhibitory activity (GIA) was significantly 
higher in the sero-high (median 21.8%, IQR 8.15-29.65) than in the sero-low (median 8.3%, 
IQR 5.6-10.23) (p=0.025).  
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Conclusion 
CHMI was safe and well tolerated in this population. Individuals with serological evidence of 
higher malaria exposure were able to better control infection and had higher parasite growth 
inhibitory activity.  
 
 
Key words: malaria exposure, parasite kinetics, clinical outcomes, functional antibodies, 
controlled human malaria infection 
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BACKGROUND  
Naturally acquired immunity against malaria parasites, which limits high-density parasitemia and 
severe disease, develops after repeated exposure, and more rapidly in high than in low 
transmission areas [1, 2]. This immunity is thought to be primarily mediated by anti-blood stage 
antibodies, which reduce parasite multiplication and cytoadherence of infected erythrocytes to 
endothelial cells [3]. In contrast, there is limited evidence for immunological responses 
preventing blood stage infection by neutralizing sporozoites and liver-stage parasites [4, 5]. 
Over the past two decades malaria control measures have led to substantial reductions in malaria 
burden [6], with several endemic countries transitioning from high-to-low malaria transmission 
[7, 8]. Decreased malaria exposure leads to increased susceptibility to infection and severe 
disease [9, 10], and is associated with decreased levels of antibodies to blood-stage antigens [11-
13].  
Controlled human malaria infection (CHMI) of healthy volunteers by exposure to the 
bites of infected, laboratory-reared Anopheles mosquitoes or inoculation of infected erythrocytes 
has been used for nearly 100 years to investigate malaria pathophysiology and immunology and 
efficacy of vaccines and drugs [14, 15].   During the last decade CHMI studies have been 
expanded in the US and Europe and increasingly performed in Africa using injectable, aseptic, 
purified, cryopreserved, vialed Plasmodium falciparum sporozoites (PfSPZ, Sanaria® PfSPZ 
Challenge)[5, 16-20], including assessment of innate resistance [5], naturally acquired immunity, 
and pre-erythrocytic and asexual erythrocytic stage vaccines [20, 21]. In this study we assessed 
how exposure to P. falciparum, as measured by serology to six pre-defined antigens, affected 
parasite kinetics, clinical symptoms, and functional immunity after CHMI by direct venous 
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inoculation (DVI) of PfSPZ Challenge [16, 17] in  Gambian adult males with markedly different 
levels of previous malarial exposure. 
 
METHODS 
Study Design and participants 
This was an open-label, non-randomized clinical trial, conducted at the Medical Research 
Council Unit The Gambia (MRCG). Healthy male participants aged 18–35 years were recruited 
between 13
th
 and 23
rd
 March 2018. Volunteers were preferentially recruited from tertiary 
learning institutions and provided written informed consent before screening. Eligible volunteers 
had normal haematological and biochemical tests and no abnormalities by electrocardiogram. 
Participants had to be P. falciparum negative by molecular methods on two occasions, at 
recruitment and just before DVI. Previous individual P. falciparum exposure was assessed using 
serologic responses to a panel of P. falciparum antigens using a Luminex platform [22]. These 
included responses associated with cumulative exposure, namely  apical membrane antigen-1 
(AMA-1), merozoite surface protein1.19 (MSP1.19) and glutamate-rich protein (GLURP.R2) 
[23], and responses associated with malaria infection in the past 6 months, namely reticulocyte-
binding protein homologue (Rh2.2030), gametocyte exported protein (GEXP18) and Early 
transcribed membrane protein (Etramp5.Ag1) [24]. A complete description of the eligibility 
criteria is provided in Supplementary Appendix 1.  The study received approval from the 
Scientific Coordinating Committee of MRCG, the Gambia Government/MRCG Joint Ethics 
Committee, and the London School of Hygiene and Tropical Medicine (LSHTM) Research and 
Ethics committee and was conducted according to the International Conference on 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz740/5546068 by guest on 31 August 2019
 7 
 
Harmonization – Good Clinical Practice (ICH-GCP) guidelines and registered with 
ClinicalTrials.gov, Identifier: NCT03496454. 
Study Objectives 
The primary objectives were to assess the feasibility of the CHMI model in The Gambia and 
determine the parasite kinetics in naturally exposed Gambian adults after PfSPZ Challenge 
administration. Secondary objectives were to analyse humoral and cellular immune responses 
and their association with time to patency and parasite density at time of first detection, and to 
assess frequency, incidence, nature and magnitude of adverse events.  
PfSPZ Challenge 
Sanaria® PfSPZ Challenge is composed of aseptic, purified, vialed, cryopreserved, fully 
infectious NF54 PfSPZ isolated from Anopheles stephensi mosquitoes [16, 18, 25]. PfSPZ 
Challenge was supplied by Sanaria Inc. as 20µL cyrovials containing 15,000 PfSPZ and stored in 
liquid nitrogen vapor phase at -150° to -196°C [25]. For this study, only one lot of PfSPZ 
manufactured on 30
th
 April 2015 was used. The potency (capacity to invade and fully develop in 
cultured human hepatocytes (HC-04)) and viability (sporozoite membrane integrity) of this lot 
were tested as detailed in Supplementary Appendix 2.   
Study Procedures 
All screened volunteers were ranked by the cumulative quartile score of the mean fluorescent 
intensities of the six pre-defined antigens [24]. Volunteers with the highest and lowest scores, 
were assigned to the sero-high and sero-low groups, respectively. This classification resulted in 
significantly higher responses to all individual antigens reflected by mean fluorescent intensities 
of cumulative and recent exposure markers that were 4-13-fold and 3-5-fold higher respectively 
in the sero-high group (Supplementary Appendix 3). Whilst populations were defined based on a 
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cumulative quartile score for all antigens combined, recognition was also statistically 
significantly higher for the high exposure population for each of the 6 individual antigens 
(p<0.014); (Figure 1). All volunteers received PfSPZ Challenge (3.2 x 10
3
 PfSPZ in 0.5 mL) by 
DVI through a 25-gauge needle performed on a single day (29
th
 March 2018) following 
Sanaria’s standard operating procedures. After injection, participants were observed for 1 hour 
and subsequently closely monitored on an outpatient basis, with regular visits to the study clinic. 
Participants were instructed to register their daily symptoms in a study diary, measure 
temperature twice daily and contact the clinical investigators when any symptoms occurred. 
From day 5 post-injection onwards, participants were seen twice daily until day 15, and daily 
until day 28 or day of treatment. At each follow-up visit, temperature was taken, adverse events 
(AEs) recorded, and blood samples collected; physical examination was done on indication. 
Participants had a mobile phone by which they could be contacted. As an additional safety 
precaution, participants stayed in a hostel close to the study clinic from the day of infection until 
3 days after treatment. The following signs and symptoms were solicited at all visits: fever, 
headache, malaise, fatigue, dizziness, myalgia, arthralgia, nausea, vomiting, chills, diarrhoea, 
abdominal pain, chest pain, palpitations and shortness of breath [26]. AEs were reported as mild 
(grade 1, easily tolerated), moderate (grade 2, interfered with normal activity), or severe (grade 
3, prevented normal activity); for fever, as grade 1 (>37.5 °C to 38.0 °C), grade 2 (38.1 °C to 
39.0 °C), or grade 3 (> 39.0 °C). Laboratory values were graded using the DAIDS Table for 
Grading the Severity of Adult and Paediatric Adverse Events Version 2.1 March 2017.   
If a thick blood smear (TBS) was positive with any parasitaemia, with or without signs and 
symptoms of malaria, treatment with artemether-lumefantrine was started immediately. 
Participants who did not develop parasitaemia by day 28 received artemether-lumefantrine on 
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that day. Treatment was directly observed, and all participants were seen at day 35 for an end of 
study visit.  
Blood sampling and laboratory assessments  
Screening for parasitaemia by microscopic examination of TBS and quantitative polymerase 
chain reaction (qPCR) was done twice daily from days 5 to 15 and daily from days 16 to 28. A 
complete blood count was done the day prior to PfSPZ Challenge injection, every three days 
between days 5-28, just before treatment and thereafter daily for the following three days and at 
day 35. Blood biochemistry was performed one day before PfSPZ Challenge injection, two days 
after treatment and at day 35. To check if volunteers had self-medicated with artemether-
lumefantrine, lumefantrine levels were measured at baseline by high performance liquid 
chromatography with photodiode array detection [27]. Peripheral blood mononuclear cells were 
collected for immunological studies one day before PfSPZ Challenge injection and at day 35. 
Malaria infection was defined as asexual parasites in peripheral blood by TBS during the study 
and by qPCR retrospectively. The prepatent period was defined as the time between PfSPZ 
Challenge injection and first positive qPCR. TBS were performed according to an internationally 
harmonized protocol for thick smears in CHMI studies [28].  qPCR was done retrospectively 
using established methodologies [29] and  considered positive at a parasite threshold of ≥ 5 
parasites per mL.  
Immunological assays 
Assessment of sporozoite invasion inhibition by volunteer serum samples was done  as described 
previously [30, 31] and in Supplementary Appendix 4. Antibody levels in citrate plasma from 
volunteers at baseline were measured by enzyme-linked immunosorbent assay (ELISA) to NF54 
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sporozoite or schizont extract. Growth inhibition was determined by invasion/growth inhibition 
assays (GIA) as described in Supplementary Appendix 4.   
 
Sample size estimation and statistical analysis 
Sample size calculation was based on the difference in prepatent period between groups. 
Assuming a mean time to qPCR positivity of 7.1 days (SD 0.8 days) [32], it was estimated that 
15 participants per cohort would be sufficient to detect a 1-day longer time to first detection of 
parasites by qPCR in the high exposure group (8.1 days), with 90% power and alpha of 0.05. 
Due to low numbers of participants presenting for screening and volunteers not meeting 
eligibility criteria just before study start, only 19 volunteers were enrolled. Prepatent period and 
parasite density at first detection by qPCR were compared between groups using the log-rank 
test.  For the immunological analyses, differences were assessed by comparing mean values 
between groups or time points using either a two-tailed Student’s t-test or non-parametric 
equivalents.  Time to patency and parasite density at first detection of infection were associated 
with immune responses.  
 
RESULTS 
Study population 
Eighty-four volunteers were screened; of these, 8 were qPCR positive during screening. Nineteen 
volunteers at the extremes of the immunological spectrum (Supplementary Appendix 3) were 
enrolled into the study; 9 in the sero-high- and 10 in the sero-low group (Supplementary 
Appendix 5).  Baseline characteristics are shown in Table 1. Most of the volunteers resided in the 
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West Coast region, an area previously reported to have low transmission compared to the other 
regions [33]. However, malaria transmission in The Gambia is highly heterogenous with both 
high- and low-exposed individuals in all regions. Volunteers in the sero-high group were older 
than those in the sero-low group; mean age 25.7 years (SD 3.3) vs. 22.6 years (SD 2.3) 
respectively, p = 0.028.  
Parasite kinetics and clinical malaria 
Seventeen of the 19 volunteers (89%) developed parasitemia detected by microscopy in the first 
28 days of follow up: all individuals in the sero-low group (100%; 10/10) and 7 (77.8%; 7/9) in 
the sero-high group (p = 0.125), Table 2. One of the two volunteers who remained microscopy 
negative was qPCR positive at day 18 (Figure 2A and 2B). All volunteers reported no prior or 
current use of antimalarial drugs and none had measurable concentrations of lumefantrine at 
baseline.  Median prepatent period was significantly shorter in the sero-low than in the sero-high 
group [9.0 days (SD 1.6) vs.11.0 days (SD 6.3), log rank test, p=0.005] (Table 2, Figure 2B). 
Parasite density by qPCR on day of treatment was significantly higher in the sero-low than in the 
sero-high group, p = 0.01(Figure 2C). Individual level parasite kinetics showed faster parasite 
multiplication in the sero-low group (Figure 3). Parasite multiplication rates (PMR48) were 
calculated for all available 48-hour intervals following first detection of parasites by qPCR until 
treatment. Median PMR48 were non-significantly higher in the sero-low group (p=0.143) and 
were negatively associated with antibody titres against asexual parasite lysate (r = -0.5074, 
p=0.0376), (Supplementary Appendix 6). 
 Participants in the sero-low group had a significantly higher probability of having clinical 
malaria symptoms (90.0%, 9/10) than those in the sero-high (33%, 3/9), log rank p = 0.0008 
(Table 2, Figure 4).   
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Safety and tolerability of PfSPZ Challenge 
There were minimal AEs in the first 7 days after PfSPZ Challenge. Fourteen volunteers, 5 in the 
sero-high (55.6%) and 9 in the sero-low (90.0%) group experienced 82 AEs, including 
hematological and biochemistry abnormalities, that were possibly or probably related to malaria 
(Table 3). Seventy of the 82 (85.4%) AEs occurred in the sero-low, while only 12 (14.6%) 
occurred in the sero-high group (p <0.0001). Most AEs (89.0%, 73/82) were mild to moderate 
and occurred around the time parasitemia became detectable by TBS. Moderate and severe AEs 
were only observed in the sero-low group (Table 3, Figure 4). Headache was the most frequently 
reported AE in both the sero-high (25%, 3/12) and sero-low (20%, 14/70) groups. Fever was 
only observed in the sero-low group (5/70, 7.1%), (Table 3). Of the 20 hematological and 
biochemistry abnormalities recorded, 75% (15/20) were in the sero-low and 25.0% (5/20) were 
in the sero-high group, p= 0.002. No serious AEs or cardiac AEs were reported, and all AEs had 
resolved by day 35.  
Humoral and functional immunity 
Antibody recognition of sporozoites by sporozoite-binding ELISA was significantly higher in 
plasma of sero-high (median 17.93 AU, IQR 12.95-24) compared to the sero-low volunteers 
(median 10.54 AU, IQR 8.36-12.12); (p=0.006; Figure 5A). However, the groups did not differ 
in their ability to block sporozoite invasion of HC04 hepatocytes, (sero-high: median 88.26% 
invasion, IQR 83.52-100.1%; sero-low: 91.74% invasion, IQR 90.54-103, p=0.18); (p=0.18); 
(Figure 5B). Invasion was indexed as a percentage relative to invasion in the presence of non-
immune serum from naïve donors, where 100% meant no invasion inhibition.  The presence of 
blood-stage antibodies, determined by schizont extract was also significantly higher (p=0.0003) 
in the sero-high group (median 50.98 AU, IQR 22.46-65.07; Figure 5C) than in the sero-low 
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group (median 3.16 AU, IQR 2.43-8.71). We observed indications for functional differences in 
blood-stage immune responses, with significantly higher GIA in the sero-high (median 21.8%, 
IQR 8.15-29.65) than in the sero-low (median 8.3%, IQR 5.6-10.23) (p=0.025; Figure 5D). 
Length of prepatent period correlated positively with sporozoite-binding antibody titres (r=0.64, 
p=0.003), blood-stage antibody titres (r=0.48, p=0.036) and blood-stage GIA activity (r=0.65, 
p=0.003) but not with sporozoite invasion inhibition (r= -0.29, p=0.236). For individual antibody 
responses, Rh2.2030 (r = 0.5357, p=0.018) and AMA-1 (r = 0.4959, p=0.031) were the most 
predictive of prepatent period (Supplementary Appendix 7). Significant correlation was also seen 
between the different immunological responses (Supplementary Appendix 8). 
  
DISCUSSION 
This study demonstrated the feasibility and successful implementation of CHMI with PfSPZ 
Challenge in The Gambia,  increasing the capacity of conducting such studies in endemic areas: 
CHMI with PfSPZ Challenge has now been done in 6 African countries [5, 18-21]. A study in 
Gabon with PfSPZ Challenge reported that previous exposure to P. falciparum and sickle cell 
trait both impacted the rate of blood stage infection, prepatent period, and clinical manifestations 
of malaria [5]. Whilst previous studies in Kenya also associated immune responses to parasite 
kinetics among CHMI volunteers [34], ours is the first assessment of the effect of previous 
exposure to P. falciparum as measured by a pre-defined serology panel of six antigens on 
parasite kinetics, clinical symptoms and functional immune responses. Individuals with 
serological evidence of higher recent and cumulative malaria exposure had a longer prepatent 
period, lower mean parasite density and fewer symptoms of malaria. Whereas there was 
considerable variability in individual responses, the pre-screening panel used to define exposure 
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in this population correlated directly with clinical outcomes [22].  Using functional assays for 
pre-erythrocytic immunity and blood-stage immunity, this study also sheds light on the 
mechanisms underlying these differences. Anti-sporozoite responses were higher in highly 
exposed individuals but did not translate into responses preventing liver-stage infection in vitro 
whilst antibody responses controlling blood-stage parasite multiplication in vitro were markedly 
stronger in this group. 
Understanding the impact of declining malaria exposure on malaria immunity is highly relevant 
in the context of wide-scale and often pronounced reductions in malaria burden in African and 
non-African settings [35, 36]. More direct methods for assessing immunity are needed to 
quantify the clinical consequences of declined exposure. Whilst we directly defined our cohorts 
based on serological markers that have been presented as indicators of  recent and cumulative 
exposure [24, 37], several previous studies have indirectly determined malaria exposure based on 
self-reported clinical history of malaria episodes and long-term residence in malaria endemic 
areas [5, 23] or by measuring responses to whole parasite lysate and the blood stage antigen 
MSP-2 with a very long half-life [38]. In line with our findings, these studies observed a lower 
likelihood of parasite positivity post-CHMI in the highly exposed group [5, 23, 38].  Lell and 
colleagues postulated that mechanisms for the control of parasitemia included a combination of 
adaptive immune mechanisms such as prevention of hepatocyte infection, elimination of infected 
liver cells by T-cell mediated cytotoxicity or immune mediators and highly effective clearance of 
the first generation of merozoites leaving infected hepatocytes [5].  Our study directly examined 
differences in functional pre-erythrocytic and blood-stage immunity using established 
methodologies. Though we found no evidence for differences in inhibition of sporozoite 
invasion, we observed stronger parasite growth inhibition in the sero-high cohort. Since 
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volunteers were selected based on distinct immune profiles, our functional immune parameters 
must be interpreted with caution given challenges in disentangling functional immune responses 
from markers of exposure [39]. The single volunteer who remained parasite-negative by qPCR 
had median levels of pre-erythrocytic antibodies (17.93 AU), moderate HC04 invasion 
(104.13%; mean 95.41% invasion), very low levels of asexual antibodies (5.98 AU; mean 47.42 
AU), and average GIA (23% inhibition; mean 21.94%). The striking difference in growth 
inhibition in our two cohorts suggests that functional blood-stage antibodies contributed 
significantly to the differences in clinical symptoms and parasite kinetics.  There was a weak, 
negative correlation (r= -0.4474, p= 0.0548) between levels of sporozoite-binding antibodies and 
functional invasion-blocking activity, suggesting a minor invasion-blocking role for naturally 
acquired antibodies. Sporozoite-targeting antibodies in this study may be markers of exposure 
only or may enhance cellular immunity but lack direct invasion-blocking activity.  
The systemic and laboratory AEs observed were consistent with uncomplicated malaria, with 
most AEs recorded at the time of positive microscopy. Severe symptoms, including chills, 
fatigue, malaise and headache reported in 3 sero-low volunteers were also consistent with 
uncomplicated malaria and resolved within 48 hours post-treatment. Two sero-low volunteers 
had grade 3 reductions in total lymphocyte count considered related to malaria and resolved by 
day 4 of malaria treatment. Similar declines have been reported previously  [40]. This study does 
not allow us to extrapolate findings to other populations.  
In summary, CHMI was safe and well tolerated in this population and the manifestations 
of malaria, although significantly different between the two exposure groups, were consistent 
with previous CHMI studies. Volunteers with high previous exposure to malaria infection were 
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able to better control the infection as shown by the significantly lower parasite densities, less 
severe symptoms and a lower incidence of symptoms associated with parasitemia.  
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Table 1. Demographic characteristics of volunteers enrolled in the Gambia controlled 
human malaria infection study  
 
 
 High Exposure group Low Exposure group p-value 
Number of 
participants (n) 
9 10 0.752 
Age in years (mean, 
SD) 
25.7 (3.3) 22.6 (2.3) 0.028 
Male gender:  n (%) 
Height in cm  
9 (100%) 
177.0 (174.0-182.0) 
10 (100%) 
177.0 (174.0-181.0) 
- 
0.968 
Weight in Kg  62.8 (59.8-80.1) 64.8 (52.8-86.7) 0.490 
BMI in Kg/m
2 21.0 (18-26) 20.7 (18-26) 0.936 
Ethnicity: n (%) 
     Mandika 
     Fula 
    Other 
 
2 (22.2) 
5 (55.6) 
2 (22.2) 
 
7 (70.0) 
1 (10.0) 
2 (20.0) 
 
0.043 
0.038 
0.909 
 
Residence: n (%) 
   West coast region 
   Upper river region 
   Central river region 
 
7 (77.8) 
2 (22.2) 
0 (0.0) 
 
7 (70.0) 
0 (0.0) 
3 (30.0) 
 
0.707 
0.125 
0.081 
    
Median (range) for all continuous variables except where noted 
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Table 2: Parasitological and clinical outcomes following controlled human malaria 
infection   
 
 High Exposure group 
N= 9.0 
Low Exposure group 
N = 10.0 
P value 
Number of subjects positive by 
microscopy 
7.0 (77.8%) 10.0 (100.0%) 0.125 
Number of subjects positive by 
qPCR  
8.0 (88.9%) 10.0 (100.0%) 0.292 
Days to parasitemia by 
microscopy*
 
14.0 (6.6) 13.5 (1.5) 0.327 
Days to parasitemia by qPCR* 11.0 (6.3) 9.0 (1.6) 0.016 
Days from qPCR positivity to 
microscopy positivity* 
3.0 (2.6) 5.0 (0.5) 0.156 
Number of subjects who developed 
symptoms** 
3.0 (33.3%) 9.0 (90.0%) 0.013 
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*Median (standard deviation), **only possibly or probably related to study, ***Geometric mean (range), qPCR = quantitative 
polymerase chain reaction (≥5 parasites/mL), ****The area under the curve (AUC) represents the total parasite exposure over 
time until treatment (parasite load). 
 
 
 
 
 
 
 
 
  
Peak parasite density during study 
(qPCR, parasites/mL) ***  
3748.9 (50.6-71264.3) 49340.3 (5186.5-205850) 0.088 
Area under the curve (AUC) of 
parasitemia until treatment (qPCR) 
(median (range)) **** 
8035 (0-122054) 34504 (3404-120441) 0.173 
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Table 3: Adverse events following controlled human malaria infection in the two exposure 
groups 
 Sero-high group 
N= 9 
Sero-low group 
N = 10 
Number of participants with any adverse 
events (including laboratory abnormalities) 
5.0 (55.6%) 9.0 (90.0%) 
Number of participants with adverse events 
≥ grade 2 
2.0 (22.2%) 8.0 (80.0%) 
   
Grade 1 and 2 adverse events 
Total 
 
12.0 
 
61.0 
Headache 3.0 (25.0%) 12.0 (19.7%) 
Fever 0.0 5.0 (8.2%) 
Chills 1.0 (8.3%) 4.0 (6.6%) 
Fatigue/malaise 1.0 (8.3%) 8.0 (13.1%) 
Myalgia 0.0 4.0 (6.6%) 
Arthralgia 2.0 (16.7%) 1.0 (1.6%) 
Anorexia 0.0 5.0 (8.2%) 
Nausea 0.0 2.0 (3.3%) 
Vomiting 0.0 1.0 (1.6%) 
Abdominal pain 0.0 2.0 (3.3%) 
Dizziness 0.0 3.0 (4.9%) 
Diarrhoea 0.0 1.0 (1.6%) 
Ribcage pain 0.0 1.0 (1.6%) 
Low platelet count 1.0 (8.3%) 2.0 (3.3%) 
Low lymphocyte count 1.0 (8.3%) 5.0 (8.2%) 
Low absolute neutrophil count 1.0 (8.3%) 0.0 
Elevated total bilirubin 0.0 2.0 (3.3%) 
Elevated lactate dehydrogenase 0.0 1.0 (1.6%) 
Elevated aspartate transaminase
* 
0.0 1.0 (1.6%) 
Elevated Gamma-glutamyl transferase 1.0 (8.3%) 0.0 
Elevated Sodium levels 1.0 (8.3%) 1.0 (1.6%) 
   
Grade 3 adverse events 
Total 
 
0.0 
 
9.0 
   Headache 0.0 2.0 (22.2%) 
   Chills  0.0 2.0 (22.2%) 
   Fatigue/malaise 0.0 2.0 (22.2%) 
    Low lymphocyte count 0.0 3.0 (33.3%) 
*No clinically significant elevations in alanine aminotransferase (ALT) were observed 
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Figure Legends 
Figure 1: Antibody histogram plots for screened volunteers in the Gambia controlled 
human malaria infection study** 
 
** Light colors are the sero-low group, dark colors are the sero- high group and grey colors are the other 
screened volunteers with intermediate immunological profile. 
 
 
 
Figure 2. Comparison of parasite kinetics between the two exposure groups following 
controlled human malaria infection 
 
Kaplan Meier curve for time from inoculation to parasitemia detected by thick blood smear (A) and qPCR 
(B). Differences in parasite density by qPCR at treatment (C) and peak parasitemia (D) 
 
 
 
Figure 3.  Individual level kinetics of parasitemia by qPCR following controlled human 
malaria infection  
 
 
 
 
Figure 4. Differences in clinical outcomes following controlled human malaria infection in 
the two exposure groups
§
  
 
§ 
Shows proportion of participants without symptoms, number of AEs per participant and total number of 
AEs per group 
 
 
 
 
Figure 5. Antibody-mediated responses to P. falciparum in high- and low-exposure groups 
 
 
A) The sero-high group had significantly higher (p=0.006) titres of antibodies to sporozoite antigens, expressed as 
arbitrary units (AU). (B) There were no significant differences between groups in their ability to block sporozoite 
invasion of HC04 hepatocytes. (C) Plasma from the sero-high group also had significantly higher (p=0.0003) levels 
of antibodies to asexual-stage antigens, also expressed as AU. (D) Purified IgG from the sero-high exposure group 
also had significantly higher growth inhibitory activity (p=0.025) against blood-stage 3D7 parasites.  
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Figure 4. 
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Figure 5. 
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